Fig. 1: Global trends in incidence and death for hematological malignancies from 1990 to 2019.
From: Global burden of hematologic malignancies and evolution patterns over the past 30 years
A The new cases of hematological malignancies from 1990 to 2019. B The number of deaths due to hematological malignancies from 1990 to 2019. C ASIR and EAPC in hematological malignancies over the last 30 years. D ASDR and EAPC in hematological malignancies over the last 30 years. E The proportion of new cases of hematological malignancies from 1990 to 2019. F The proportion of deaths of hematological malignancies from 1990 to 2019. ASIR age-standardized incidence rate, ASDR age-standardized death rate, EAPC estimated annual percentage change, FISH fluorescence in situ hybridization, mPCR multiplex polymerase chain reaction, ELISA enzyme-linked immunosorbent assay, FCM flow cytometry, IHC immunohistochemical, NGS Next-generation sequencing, MS mass spectrum, ctDNA circulating tumor DNA, WHO World Health Organization, IMWG International Myeloma Working Group, REAL Revised European American Lymphoma, CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone.
